Dyne Therapeutics IncNASDAQ:DYN
- LAST PRICE35.6750
- TODAY'S CHANGE (%)1.8450 (5.4537%)
- Bid / Lots35.6300/ 2
- Ask / Lots35.7200/ 1
- Open / Previous Close33.6800 / 33.8300
- Day Range
- 52 Week Range
- Volume380,411
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DYN |
|---|---|---|
| 09:32 ET | 6991 | 33.95 |
| 09:34 ET | 100 | 34.1 |
| 09:36 ET | 11577 | 34.305 |
| 09:38 ET | 51220 | 34.79 |
| 09:39 ET | 110 | 34.5 |
| 09:41 ET | 21683 | 34.685 |
| 09:43 ET | 2000 | 34.815 |
| 09:45 ET | 10800 | 34.735 |
| 09:48 ET | 2607 | 34.75 |
| 09:50 ET | 45800 | 34.77 |
| 09:52 ET | 8146 | 34.725 |
| 09:54 ET | 1285 | 34.88 |
| 09:56 ET | 435 | 34.86 |
| 09:57 ET | 800 | 34.86 |
| 09:59 ET | 1700 | 34.52 |
| 10:01 ET | 100 | 34.475 |
| 10:03 ET | 800 | 34.475 |
| 10:08 ET | 195 | 34.48 |
| 10:10 ET | 3092 | 34.44 |
| 10:12 ET | 200 | 34.455 |
| 10:14 ET | 500 | 34.57 |
| 10:15 ET | 1000 | 34.71 |
| 10:17 ET | 26084 | 34.72 |
| 10:19 ET | 900 | 34.93 |
| 10:21 ET | 750 | 34.92 |
| 10:24 ET | 300 | 34.91 |
| 10:26 ET | 1100 | 34.98 |
| 10:28 ET | 200 | 34.99 |
| 10:30 ET | 4651 | 35.07 |
| 10:32 ET | 468 | 35.2 |
| 10:33 ET | 26817 | 35.065 |
| 10:35 ET | 825 | 35.24 |
| 10:37 ET | 200 | 35.195 |
| 10:39 ET | 500 | 35.15 |
| 10:42 ET | 5783 | 35.205 |
| 10:44 ET | 1971 | 35.07 |
| 10:48 ET | 100 | 35.12 |
| 10:50 ET | 100 | 35.065 |
| 10:51 ET | 3500 | 34.8393 |
| 10:53 ET | 378 | 34.93 |
| 10:55 ET | 100 | 34.885 |
| 10:57 ET | 220 | 35 |
| 11:00 ET | 200 | 35.01 |
| 11:02 ET | 100 | 35 |
| 11:04 ET | 200 | 34.995 |
| 11:06 ET | 934 | 35.07 |
| 11:09 ET | 135 | 35.025 |
| 11:11 ET | 530 | 35.02 |
| 11:13 ET | 500 | 35.135 |
| 11:15 ET | 16564 | 35.185 |
| 11:18 ET | 1762 | 35.38 |
| 11:20 ET | 438 | 35.385 |
| 11:22 ET | 10149 | 35.25 |
| 11:24 ET | 20211 | 35.49 |
| 11:26 ET | 2100 | 35.485 |
| 11:27 ET | 5127 | 35.56 |
| 11:29 ET | 750 | 35.645 |
| 11:31 ET | 5700 | 35.71 |
| 11:33 ET | 600 | 35.71 |
| 11:36 ET | 200 | 35.7 |
| 11:38 ET | 1890 | 35.74 |
| 11:40 ET | 500 | 35.76 |
| 11:42 ET | 10929 | 35.675 |
Today
Yesterday
The Schall Law Firm Invites Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Violating Securities Laws, from 11:06AM ET on Sunday Sep 29, 2024 by Dow Jones
11:06AM ET on Sunday Sep 29, 2024 by Dow JonesSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN, from 10:04AM ET on Sunday Sep 29, 2024 by Dow Jones
10:04AM ET on Sunday Sep 29, 2024 by Dow Jones
Sep 28, 2024
Sep 27, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN, from 5:42PM ET on Friday Sep 27, 2024 by Dow Jones
5:42PM ET on Friday Sep 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Dyne Therapeutics Inc | 3.4B | -10.0x | --- |
MoonLake Immunotherapeutics | 3.3B | -56.7x | --- |
Biohaven Ltd | 3.7B | -5.5x | --- |
Iovance Biotherapeutics Inc | 3.1B | -5.8x | --- |
Merus NV | 3.4B | -17.3x | --- |
Xenon Pharmaceuticals Inc | 3.1B | -14.0x | --- |
Company Information
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.
Contact Information
- Headquarters
- 1560 Trapelo RoadWALTHAM, MA, United States 02451
- Phone
- 781-786-8230
- Fax
- 781-786-8866
Executives
- Independent Chairman of the Board
- Jason Rhodes
- President, Chief Executive Officer, Director
- John Cox
- Chief Operating Officer
- Susanna High
- Chief Human Resource Officer
- Lucia Celona
- Senior Vice President, Head of Finance and Administration
- Richard Scalzo
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 100.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $-3.58 |
Book Value | $1.49 |
P/E Ratio | -10.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
